Opus Genetics Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of APX3330 In Diabetic Retinopathy; Agreement Reached On Primary Endpoint And Phase 3 Trial Design

BenzingaDec 19 21:06

Express News | Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of Apx3330 in Diabetic Retinopathy

BreakingsDec 19 21:00

Buy Rating Affirmed for Opus Genetics Amid Promising OPGx-LCA5 Treatment Results and Regulatory Progress

TipRanksDec 16 20:35 · Ratings

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)

TipRanksDec 15 23:50 · Ratings

Analysts' Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)

TipRanksDec 15 23:40 · Ratings

HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

BenzingaDec 12 19:29 · Ratings